Barely Significant
← all excerpts

Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine.

Front Pharmacol · 2019 · PMC6400831 · PMID 30873022

Europe PMCDOI
1
hedged sentence
0.1240
closest p · 2.5× alpha
0.1240
boldest claim

The sentences

a positive trendp = 0.124not close (p > 0.1)
A first Phase III trial did not deliver any significant changes in FEV 1 although there was a positive trend favoring Ataluren ® (-2.5% change) over the placebo (-5.5% change; p = 0.124) ( Wilschanski et al., 2011 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.